Gene editing-based oncology therapeutics developer KSQ Therapeutics has initiated the first patient treatment in a Phase I/II clinical trial of its new candidate, KSQ-001EX. It is a tumor-infiltrating lymphocyte (TIL) therapy with the SOCS1 gene inactivated by CRISPR/Cas9 gene editing, developed as a potential treatment for various solid tumor conditions.
The trial is carried out in two phases: Phase I, evaluating the safety and tolerability of KSQ-001EX, and Phase II, evaluating antitumor activity in indication-specific cohorts. The clinical trial is an open-label, safety lead-in study for patients with melanoma, head-and-neck squamous cell carcinoma (HNSCC), and non-small-cell lung cancer (NSCLC).
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.